ArticleJournal of anesthesia, analgesia and critical care2026
Relationship between norepinephrine dose and outcome in septic shock: a retrospective study.
Article in Journal of anesthesia, analgesia and critical care, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHigh-dose norepinephrine (NE) is frequently required in septic shock, but the association of NE dose with outcome remains incompletely characterised. We aimed to evaluate the relationship between NE dosing, mortality and ischemic complications, and to identify clinically relevant NE dose ranges.
methodsThis retrospective single-centre cohort study included adult patients (≥ 18 years) admitted to the Intensive Care Unit (ICU) between 2016 and 2022 with septic shock on admission, complete data on NE dosing and ICU mortality; patients receiving mechanical circulatory support were excluded. NE dosing variables (initial-dose, highest dose within 24 h, and peak ICU-dose) were collected. Adjusted optimal binning was used to identify NE peak-dose ranges associated with ICU and in-hospital mortality. Multivariable logistic regression was adjusted for age, APACHE II, and SOFA score, and time-dependent Cox models assessed associations with secondary ischemic outcomes.
resultsA total of 506 patients were included. Median NE peak-dose was 0.5 [0.2-1.2] µg/kg*min. Four NE peak-dose ranges were identified: 0.05-0.6, 0.61-1.2, 1.2-3.0, and > 3.0 µg/kg*min. ICU and in-hospital mortality increased stepwise across these ranges, from 20.7 and 32.4% in the lowest group to 100% in patients receiving > 3.0 µg/kg*min. This association persisted after exclusion of patients with withdrawal of life-sustaining therapies. Adjusted odds ratios for ICU mortality were 1.88 [0.97-3.64] and 2.55 [1.38-5.57] in the 0.61-1.2 and 1.2-3.0 µg/kg*min groups, respectively. NE peak-dose showed fair discrimination for ICU mortality (AUROC of 0.75), with an optimal Youden threshold of 0.78 µg/kg*min. Most ischemic complications were infrequent and not dose dependent, except for myocardial ischemia and unexpected cardiac arrest, which were significantly associated with higher NE doses.
conclusionsIn septic shock, increasing NE peak-doses are associated with a significant stepwise increase in ICU and in-hospital mortality across four distinct dose ranges. Ischemic complications are uncommon and largely independent of NE dose.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.